Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.

The EMBO journal - 15 May 2018

Miettinen Teemu P, Peltier Julien, Härtlova Anetta, Gierliński Marek, Jansen Valerie M, Trost Matthias, Björklund Mikael

Abstract excerpt

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism responsible for palbociclib-induced senescence, we performed thermal proteome profiling of MCF7 breast cancer cells. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Senescence
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 6

Share to Piperazines

Share to Proteasome Endopeptidase Complex

Share to Proteome

Share to Pyridines

Share to Ubiquitin

Source

Open in PubMed Open full text

Identifiers

PMID: 29669860
DOI: 10.15252/embj.201798359
PMCID: PMC5978322

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.PMID 29669860Read ↗

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclibSemantic proximity Read ↗

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read ↗

Proteasome dysregulation in human cancer: implications for clinical therapiesSemantic proximity Read ↗

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell ResponseSemantic proximity Read ↗

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancerSemantic proximity Read ↗

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionSemantic proximity Read ↗

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read ↗

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a reviewSemantic proximity Read ↗

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read ↗

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cellsSemantic proximity Read ↗

Network integration of thermal proteome profiling with multi-omics data decodes PARP inhibitionSemantic proximity Read ↗

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.